American Society of Hirudotherapy

Substrate-Guided Design of Selective FXIIa Inhibitors Based on the Plant-Derived Momordica cochinchinensis Trypsin Inhibitor-II (MCoTI-II) Scaffold

Research article published in Journal of medicinal chemistry (2016)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Research reportDrug DevelopmentSwedberg et al. · Journal of medicinal chemistry, 2016

Abstract

Thrombosis is a leading cause of morbidity and mortality associated with cardiovascular diseases. Inhibition of factor XIIa (FXIIa) provides thrombus protection without bleeding complications. Here, we defined the extended substrate specificity of FXIIa and its close homologue factor Xa and used these data, together with inhibitor-based and structure-guided methods, to engineer selective FXIIa inhibitors based on Momordica cochinchinensis trypsin inhibitor-II.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsBlood ProteinsDose-Response Relationship, DrugDrug DesignFactor XIIaHumansMolecular Dynamics SimulationMomordicaOligopeptidesStructure-Activity Relationship

Summary

Researchers defined the extended substrate specificity of factor XIIa and its homologue factor Xa, then used these data with inhibitor-based and structure-guided methods to engineer selective FXIIa inhibitors based on the Momordica cochinchinensis trypsin inhibitor-II scaffold.

Why This Matters for Hirudotherapy

This study mapped the extended substrate specificity of coagulation factor XIIa (and its homologue factor Xa) and used that data with structure-guided methods to engineer selective FXIIa inhibitors built on the plant-derived Momordica cochinchinensis trypsin inhibitor-II scaffold; the abstract notes that inhibiting FXIIa offers thrombus protection without the bleeding complications seen with conventional anticoagulants. For hirudotherapy and the broader leech-secretome drug-discovery story, the work is relevant context because it validates the same therapeutic logic that motivates research into leech-derived anticoagulants such as hirudin and the FXIIa/contact-pathway inhibitors found in leech saliva: targeting the intrinsic contact pathway to separate antithrombotic benefit from bleeding risk. As an honest caveat, this is a preclinical protein-engineering and enzymology study using a plant-based (not leech-derived) scaffold, and it does not test efficacy or safety in patients, so it speaks to a shared scientific rationale rather than to any clinical use of medicinal leeches.

Citation

Reference (Vancouver style)

Swedberg JE, Mahatmanto T, Abdul Ghani H, de Veer SJ, Schroeder CI, Harris JM, et al. Substrate-Guided Design of Selective FXIIa Inhibitors Based on the Plant-Derived Momordica cochinchinensis Trypsin Inhibitor-II (MCoTI-II) Scaffold. J Med Chem. 2016;59(15):7287-7292. doi:10.1021/acs.jmedchem.6b00557. PMID: 27434175

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 28, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.